Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain

Cancer Pain Clinical Trial

— IMPORTANCE  

Official title:

IMPORTANCE Trial - A Provisional Study-design of a Single-center, Phase II, Double-blinded, Placebo-controlled, Randomized, 4-week Study to Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04666623
• Other study ID #: ch20Benitez2
• Status: Withdrawn
• Phase: Phase 2
• Start date: November 25, 2020
• Est. completion date: October 11, 2023

Study information

• Verified date: October 2023
• Source: University Hospital, Basel, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to assess the efficacy and safety of a four-week treatment with intranasal esketamine (56 mg) twice a week combined with opioid analgesic and adjuvant standard therapy in the management of adult patients with severe and opioid refractory chronic cancer pain.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 11, 2023
• Est. primary completion date: October 11, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient with refractory cancer pain, this pain defined when:

• Multiple evidence- based biomedical therapies used in a clinically appropriate and acceptable fashion have failed to reach treatment goals that mainly include adequate pain reduction and/or improvement in daily living functioning activities.

• Patients' functional activities do not allow a quality of life which is acceptable and/or pharmaceutical therapies have resulted in intolerable adverse effects.

• Psychiatric disorders and psychosocial factors that could influence pain outcomes have been assessed and appropriately addressed

• Cancer pain classified as chronic (persistent or recurrent pain lasting longer than 3 months), and currently refractory despite optimized analgesic therapy including an opioid.

• Optimized analgesic therapy is arbitrarily defined as: oral morphine equivalent of 60 mg/d or more (or another strong opioid at optimized dose) plus at least one adjuvant analgesic drug, for at least 2 weeks.

• No increase in baseline long acting opioid dose or addition of a new adjuvant analgesic drug within 2 weeks prior to study entry

• Ability to communicate the intensity of pain using the NPRS pain scale ranging from (0 as no pain to 10 with severe pain).

• Ability to give fully informed written consent.

• Expect survival more than 3 months.

Exclusion Criteria:

• History of allergy or intolerance to esketamine or ketamine.

• History of allergy to disinfecting products containing quaternary ammonium, who might be susceptible to be allergic to denatonium benzoate.

• Concomitant use of xanthine derivatives (e.g. aminophylline, theophylline), ergometrine, or monoamine oxidase inhibitors.

• Active nasal/sinus dysfunction (e.g. allergic or infectious rhinitis) or presence of any lesion of the nasal mucosa.

• Pregnancy, breastfeeding and women of childbearing potential not using a highly effective contraception method.

• Uncontrolled hypertension, arrhythmia, heart failure, or untreated coronary artery disease. History of transient ischemic attacks, stroke, neurovascular disease, hemorrhage, severe head injury, hydrocephalus or elevated intracranial pressure within the last 3 months.

• History of primary or metastatic malignant brain lesions (uncontrolled or without previous treatment).

• Known aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels) or arteriovenous malformation

• Uncontrolled psychiatric illness with psychosis/ hallucination (e.g. schizophrenia, acute psychosis).

• Alcohol abuse, drug abuse/ dependence within the past 6 months as self-reported.

• Cirrhosis or severe hepatic impairment defined as 5-fold elevation of transaminases

• Uncontrolled hyperthyroidism.

• Globe injuries or increased intraocular pressure (e.g. glaucoma).

• History of ulcerative or interstitial cystitis.

• Subjects scheduled to receive radiotherapy (RT) to a site of pain during the study period, or who have received RT to a site of pain within 2 weeks before study entry.

• Subjects scheduled to undergo surgical treatment during the study period likely to affect pain.

• Subjects on or starting chemotherapy if there is a significant expectation of that therapy affecting pain.

• Subjects who have not provided signed informed consent form.

• Concomitant use of drugs moderately or severely affecting cytochrome P450 activity.

Related Conditions & MeSH terms

• Cancer Pain
• Pain, Intractable

Intervention

Drug:
• esketamine nasal spray
unlabeled nasal injectors, each device will deliver 28mg of esketamine in a 200 µL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
• placebo nasal spray
unlabeled nasal injectors, each device will deliver 28mg of placebo in a 200 µL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.

Locations

Country	Name	City	State
Switzerland	University Hospital Basel, Klinik für Mund-, Kiefer- und Gesichtschirurgie	Basel

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the eleven point Numeric Pain Rating Scale (NPRS)	Change in the eleven point Numeric Pain Rating Scale (NPRS): assess pain intensity at enrollment and at each visit. Patients will be asked to rate their weekly pain on a scale from 0 to 10 where 0 equals "no pain" and 10 equals "the worst pain they can imagine. NPRS will be taken for both, during physical activity and at rest.	4 consecutive weeks (from Baseline to week 4)
Secondary	Rescue morphine use	The use of morphine rescue (whether it will be reduced, no change, or increased). This will be monitored using either the Aircure artificial intelligence through a mobile application or personal diaries.	4 consecutive weeks (from Baseline to week 4)
Secondary	Change in Brief Pain Inventory (BPI)	Patients' functional status and satisfaction will be measured by the change in Brief Pain Inventory (BPI). (0 = no pain; 10 = pain as bad as you can imagine); No scoring algorithm, but "worst pain" or the arithmetic mean of the four severity items can be used as measures of pain severity; the arithmetic mean of the seven interference items can be used as a measure of pain interference.	4 consecutive weeks (from Baseline to week 4)
Secondary	Change in Patient Health Questionnaire (PHQ9)	Change in depression score using the Patient Health Questionnaire (PHQ9) at enrollment and at each visit. It scores each of the nine depression criteria as "0" (not at all) to "3" (nearly every day).	4 consecutive weeks (from Baseline to week 4)
Secondary	Change in Side Effect Rating Scale for Dissociative Anesthetics (SERSDA)	Change in Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) at enrollment and at each visit. It assesses fatigue, dizziness, headache, nausea, changes in vision and mood changes (0 = side effects absent and 4 = adverse effect is bothersome).	4 consecutive weeks (from Baseline to week 4)